📊 CNBX Key Takeaways
Investment Thesis
CNBX is in severe financial distress with negative stockholders' equity of -$2.6M, liabilities exceeding assets, and virtually no revenue generation. The company is burning cash with -$47.4K operating cash flow and has negligible liquid assets of $7.7K, indicating imminent solvency risk.
CNBX Strengths
- Minimal capital expenditure suggests no major cash drains from asset purchases
- Some form of continued operations despite extreme financial stress
- Extremely low absolute debt levels relative to industry
CNBX Risks
- Negative stockholders' equity indicates technical insolvency and balance sheet impairment
- Zero revenue generation with no meaningful profitability pathway visible
- Severe liquidity crisis with current ratio of 0.00 and only $7.7K cash against $586.2K liabilities
- Negative operating cash flow of -$47.4K indicates ongoing cash burn
- No insider confidence demonstrated by absence of Form 4 filings in last 90 days
- Negative ROA of -1018.8% shows extreme asset value destruction
Key Metrics to Watch
- Stockholders equity trajectory - recovery toward positive is critical
- Operating cash flow trend - must return to positive sustainability
- Revenue generation initiatives - any meaningful revenue would be positive signal
- Cash burn rate and runway - how long until cash depletion at current burn rate
- Debt restructuring or capital injection announcements
CNBX Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CNBX Profitability Ratios
CNBX vs Healthcare Sector
How CNBX Pharmaceuticals Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CNBX Balance Sheet & Liquidity
CNBX 5-Year Financial Trend
5-Year Trend Summary: CNBX Pharmaceuticals Inc.'s revenue has grown significantly by 1,221% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.02 indicates the company is currently unprofitable.
CNBX Growth Metrics (YoY)
CNBX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | N/A | -$34.4K | $0.00 |
| Q3 2025 | N/A | -$59.7K | $0.00 |
| Q2 2025 | N/A | -$69.8K | $0.00 |
| Q1 2025 | N/A | -$34.4K | $0.00 |
| Q2 2024 | N/A | -$325.5K | $-0.01 |
| Q1 2024 | N/A | -$178.5K | $0.00 |
| Q3 2023 | N/A | -$154.7K | $-0.02 |
| Q3 2021 | N/A | -$725.7K | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
CNBX Capital Allocation
CNBX SEC Filings
Access official SEC EDGAR filings for CNBX Pharmaceuticals Inc. (CIK: 0001343009)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CNBX
What is the AI rating for CNBX?
CNBX Pharmaceuticals Inc. (CNBX) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CNBX's key strengths?
Minimal capital expenditure suggests no major cash drains from asset purchases. Some form of continued operations despite extreme financial stress.
What are the risks of investing in CNBX?
Negative stockholders' equity indicates technical insolvency and balance sheet impairment. Zero revenue generation with no meaningful profitability pathway visible.
What is CNBX's revenue and growth?
CNBX Pharmaceuticals Inc. reported revenue of $0.0.
Does CNBX pay dividends?
CNBX Pharmaceuticals Inc. does not currently pay dividends.
Where can I find CNBX SEC filings?
Official SEC filings for CNBX Pharmaceuticals Inc. (CIK: 0001343009) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CNBX's EPS?
CNBX Pharmaceuticals Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.